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Reply
We thank Dr. Erba and colleagues as well as Dr. Sharma for their
interest in our paper (1). In the letter from Dr. Erba and colleagues,
they suggested different rates of false-positive and false-negative
results with 18F-fluorodeoxyglucose (FDG) positron emission
omography (PET)/computed tomography (CT). We agree that
iagnosis of device infection should not be limited to a single test.
onventional testing, clinical judgment, and practice according to
uidelines remain critical. However, our published data and
dditional personal experience using this technology showed that
he addition of PET/CT could be of great value in difficult cases.
t is common to use a group of patients with higher disease
revalence to demonstrate a proof of concept. Tests were also
erformed in 2 lower-risk control groups with recent device surgery or
o active infection. We are aware that Ploux et al. (2) had FDG
ptake on leads in 7.5% of controls; however, no information is
vailable on recent antibiotic use, whether attenuation-corrected
r noncorrected images were used, and follow-up duration
ecause this observation could be related to early signs of
nfection. The negative predictive value of PET/CT is useful, as
emonstrated in our study of 10 patients having an excellent
volution with no late recurrence following conservative treat-
ent at 15 months. Further studies are required to better
nderstand causes for false-positive and false-negative results.
ur study was not powered to examine the sensitivity/specificity
f PET/CT with different micro-organisms. Head-to-head com-
arison between 99mTc–hexamethylpropyleneamine oxime–
leukocyte single-photon emission CT/CT and 18F-FDG
PET/CT could be useful. There was no bias in patient recruitmentbecause all patients were recruited consecutively. All patients were
followed up until the end of the study. In conclusion, we do not
believe that PET/CT is a “magic” test, but it should now be
considered as an additional tool for decision making.
In response to the second letter by Dr. Sharma, our study was
not intended to evaluate the impact of hyperglycemia on PET/CT.
Patients with blood glucose 8 mmol/l (144 mg/dl) received
intravenous rapid-acting insulin 1 h prior to FDG injection. All
patients underwent PET/CT within 48 h of initiation of antibiotic
therapy. However, we agree that prior antibiotic therapy could
have an impact on test results. False-positive results can occur with
Dacron pouches, inflammation, or hematoma, but FDG uptake is
usually higher with infection. We agree that further studies with
longer follow-up are required. We do not believe that PET/CT
should be used in all cases, but it appears useful in patients with
cardiac device and fever of unknown origin, as well as in patients
for which knowledge of the extent of infection could change the
decision to perform device and lead extraction.
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